Canagliflozin/Metformin Hydrochloride

卡格列净/盐酸二甲双胍

Report date: 2026/05/26 20:00:28

Base Information

Drug NameCanagliflozin/Metformin Hydrochloride
Drug Alias NameTA-7284/metformin hydrochloride坎格列净/二甲双胍Canagliflozin Hemihydrate/Metformin Hydrochloride坎格列净•二甲双胍Canagliflozin • Metformin Hydrochloride +[8] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsSodium/glucose cotransporter 2 inhibitors
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Aortic Aneurysm, AbdominalCardiovascular Diseases +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2014/05/22
Country/TerritoryUnited StatesTaiwanEU
CombinationsYes Metformin HydrochlorideCanagliflozin Hemihydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJanssen-Cilag International NvSagimet Biosciences IncJanssen Pharmaceuticals Inc
Inactive CompaniesJanssen Research & Development LlcJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsDiabetes Mellitus, Type 2Aortic Aneurysm, AbdominalCardiovascular Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeA10BD16
Related LinksKEGG